Drugmaker Merck reports quarterly results Thursday morning as fears grow over the expiration of the patent on its top-selling ...

In the last two years, Merck has beaten EPS estimates 88% of the time, and revenue estimates 100% of the time. Meanwhile, ...

Merck & Co. Chief Executive Officer Robert Davis was tired of talking about China.On an earnings call in February, he ...

Over the past five years, the stock has recorded a negative one-day return in 65% of cases, with a median decline of -2.4% ...

Momentum stocks are nursing a hangover, and value investing is finally crashing the afterparty. Prem Watsa, the Canadian ...

Cantor Fitzgerald analyst Carter Gould initiated coverage of Merck (MRK) with a Neutral rating and $85 price target Shares have been “a ...

Merck is growing pharma sales and expanding margins, led by strong KEYTRUDA performance and cost discipline. Read more about ...

The global pharmaceutical industry could generate about $1.2 trillion in sales in 2025, according to Statista, and projections call for 4.7% annual growth through 2029. The cancer treatment ...

Following the firm’s $1.75bn acquisition of radiopharmaceuticals company Mariana Oncology and the $745m deal with Ratio ...

Merck (NYSE:MRK) entered into a non-exclusive license and option agreement with Cyprumed GmbH, aiming to enhance its peptide offerings through innovative oral delivery technology. Despite this ...

We recently published a list of 10 Best Pharma Stocks to Buy for Long Term Growth. In this article, we are going to take a ...

In the first meeting of the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP) ...